May 29, 2008

MJ Biologics announces breakthrough development for new PRRS vaccine
 
 

MJ Biologics, in conjunction with the University of Minnesota, has successfully decoded the porcine reproductive and respiratory syndrome disease (PRRS) virus, which would help greatly in the development of a new inactivated subunit vaccine.

By breaking the genetic code of the PRRS virus, the Selectigen MJPPRS technology allows the production of autogeneous vaccines tailored to each unique swine production system. The technology classifies PRRS viruses by their immunological properties, allowing the creation of new custom vaccines against intra-farm mutations, which would help to reduce financial losses from new PRRS strains.

The MJPRRS vaccine has provided excellent cross protection against heterogonous strains of PRRS virus in pregnant sow control studies conducted by independent veterinarians and the University.

By using the vaccine in herds with a history of PRRS virus, prenatal loss prevention and protection against clinical disease outbreaks from new virus strains entering the herd have been achieved, according to Dr. Paul Armbrecht of Lake City Veterinary Service.